Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer Docetaxel-Based Chemo Promising in Stomach and Esophageal Cancer
Perioperative treatment with docetaxel-based triplet chemotherapy may beat anthracycline-based triplet chemotherapy in resectable gastric or gastro-esophageal junction adenocarcinoma, according to a randomized clinical trial.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Surgery | Taxotere